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Background: Although previous studies have suggested that linezolid may be effective for treating
multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB), the optimal dose of
linezolid for intractable MDR/XDR-TB is not clear.
Methods: Twenty-four patients with intractable MDR/XDR-TB were treated with a daily 300 mg dose of
linezolid as part of their anti-TB drug regimen.
Results: The patients were treated with linezolid for a median duration of 359 days [interquartile range
(IQR) 268–443 days]. Seventeen (71%) patients received 300 mg of linezolid once daily from the begin-
ning of treatment for a median duration of 289 days (IQR 233–405 days). Of these patients, four developed
peripheral neuropathy, one of whom discontinued linezolid. In seven (29%) patients, 600 mg/day linezolid
was administered initially for a median duration of 104 days (IQR 26–145 days) followed by 300 mg/day
linezolid for a median duration of 348 days (IQR 298–427 days). In five of these seven patients, the reason
for changing from 600 to 300 mg/day was due to side effects of 600 mg/day linezolid (peripheral neuropa-
thy in four patients and leucopenia in one patient). After reducing the dose to 300 mg/day, linezolid could
be continued in six of the seven patients. Negative sputum conversion was achieved in 22 (92%) patients
after a median of 89 days from the start of linezolid treatment (IQR 48–160 days).
Conclusions: A daily 300 mg dose of linezolid may be useful for increasing the chances of culture con-
version in the treatment of patients with intractable MDR/XDR-TB and might have fewer side effects,
especially neurotoxicity, compared with a daily 600 mg dose of linezolid therapy. The present results
encourage further research into the use of a 300 mg dose of linezolid for MDR/XDR-TB patients.
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Introduction
Multidrug-resistant (MDR) and extensively drug-resistant
(XDR) tuberculosis (TB) is a growing clinical and public health
concern.1 These forms of TB are difficult to treat and are often
associated with a poor clinical outcome.2–4 The key problems
are the limited availability of effective drugs, the reduced effi-
cacy of second-line drugs and the increased number of adverse
reactions to them, and the long duration of therapy.
Linezolid is a recently approved anti-TB drug belonging to a
new class of antibiotics, the oxazolidinones. It has shown good
activity against Mycobacterium tuberculosis, including resistant
strains. Although previous studies have suggested that linezolid
(1200 mg/day) may be effective for treating MDR-TB and
XDR-TB,5–9 potential toxicity (e.g. myelosuppression and neuro-
toxicity) could limit its prolonged use. In recently published
studies, a daily half-dose of linezolid (600 mg/day) helped to
reduce myelosuppression, but not neurotoxicity, in patients with
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MDR/XDR-TB.10,11 The optimal dose of linezolid for intractable
MDR/XDR-TB is not clear.
In this study, we report our clinical experience with a daily
300 mg dose of linezolid therapy in combination with other
anti-TB drugs in patients with intractable MDR/XDR-TB.
Patients and methods
This study included 24 patients with MDR/XDR-TB who had pre-
viously failed to respond to treatment with second-line anti-TB
drugs. All patients who were given 300 mg/day linezolid orally as
part of their anti-TB drug regimen during the period from January
2007 to April 2008 at Samsung Medical Center (n¼13) and Asan
Medical Center (n¼11), in Seoul, South Korea, were included in
the analysis. Park et al.10 and Nam et al.11 had found that even a
daily 600 mg dose of linezolid therapy was associated with periph-
eral neuropathy in 50%–70% of MDR-TB patients. Subsequently,
a daily 300 mg dose of linezolid was prescribed from the begin-
ning of treatment of MDR-TB at our institutions. This change of
practice occurred from September 2007 in Asan Medical Center
and from October 2007 in Samsung Medical Center. This
retrospective study was approved by the Institutional Review
Board of Samsung Medical Center and Asan Medical Center.
The serum linezolid levels, including Cmin (trough level) and
Cmax (2 h after the dose), were measured at steady state using an
HPLC assay.12 The MIC of linezolid for M. tuberculosis was
determined in Middlebrook 7H10 agar using 2-fold dilutions from
0.0625 to 4 mg/L, and MIC99 was defined as the lowest concen-
tration for which the growth was ,1/100 that of the control.
Drug susceptibility testing (DST) for isoniazid, rifampicin,
ethambutol, pyrazinamide, streptomycin, kanamycin, capreomy-
cin, cycloserine, p-aminosalicylic acid, prothionamide, ofloxacin,
moxifloxacin and rifabutin was performed at the Korean Institute
of Tuberculosis, which is a World Health Organization-
designated Supranational Reference Laboratory. DST was not
performed for amoxicillin/clavulanate or clarithromycin during
the study period. DST for linezolid was determined by the pro-
portion method according to the CLSI (formerly NCCLS)13 at
the Yonsei University College of Medicine.
Results
Twenty-four patients [10 men and 14 women; median age
32 years; interquartile range (IQR) 27–36 years] were included
in the study. None of the patients was HIV-positive.
Twenty-three patients had previously failed to respond to
treatment including second-line drugs for a median of 48 months
(IQR 24–81 months), while one patient with XDR-TB was
treated with a linezolid-containing regimen after 4 months of
first-line anti-TB treatment. All of the patients had smear- and
culture-positive sputum at the start of linezolid treatment, except
one patient who had smear-negative and culture-positive
sputum. Cavitary disease on chest radiography was present in
23 (96%) patients (Table 1). Three patients had previously
undergone surgical resection for MDR/XDR-TB.
The degree of drug resistance was very high at the start of
linezolid treatment. The infecting strains of M. tuberculosis were
resistant to a median of 10 drugs (IQR 8–11). Twelve (50%)
patients had XDR-TB. Rates of resistance to ethambutol, pyrazi-
namide, streptomycin, ofloxacin and moxifloxacin were 92%,
88%, 71%, 100% and 83%, respectively (Table 2).
The median number of drugs, excluding linezolid, given to
the patients was 5 (IQR 4–6). However, the median number of
drugs to which the M. tuberculosis strain was susceptible was
only 2 (IQR 2–3), of which the median number of previously
unused drugs was 0 (IQR 0–0.5), excluding linezolid (Table 3).
The patients were treated with linezolid for a median duration
of 359 days (IQR 268–443 days). Eighteen patients were on the
linezolid treatment as of December 2008.
Seventeen (71%) patients received 300 mg of linezolid once
daily (a median of 6.4 mg/kg/day, IQR 5.0–7.1 mg/kg/day) from
the beginning of treatment for a median duration of 289 days
(IQR 233–405 days). Of these patients, four [24%; 95% confi-
dence interval (CI) 7%–50%] developed peripheral neuropathy,
three of whom continued linezolid treatment while only one
patient discontinued linezolid after 285 days of treatment. No
patient developed haematological adverse events.
In seven (29%) patients, 600 mg/day linezolid (a median
of 11.1 mg/kg, IQR 10.2–11.8 mg/kg/day) was administered
initially for a median duration of 104 days (IQR 26–145 days)
followed by 300 mg/day linezolid (a median of 5.6 mg/kg/day,
IQR 5.1–5.9 mg/kg/day) for a median duration of 348 days
(IQR 298–427 days). In five of these seven patients, the reason
for changing from 600 to 300 mg/day was due to side effects of
600 mg/day linezolid, including peripheral neuropathy in four
patients (57%, 95% CI 18%–90%) and leucopenia in one
patient. After reducing the dosage to 300 mg/day, the leucopenia
resolved completely (after the medication was stopped tem-
porally), while the paraesthesiae due to peripheral neuropathy
persisted. After reducing the dose to 300 mg/day, linezolid could
be continued in six of the seven patients. In one patient,
Table 1. Characteristics of the patients (n¼24)
Patient characteristic Number (%) or median (IQR)
Sex, male 10 (42%)
Age, years 32 (27–36)
Body mass index, kg/m2 18.8 (17.0–20.9)
Positive sputum smear 23 (96%)
Number of drugs to which the isolates were resistant 10 (8–11)
XDR-TB 12 (50%)
Bilateral disease 20 (83%)
Cavity (or cavities) on chest radiograph 23 (96%)
Linezolid for treating MDR/XDR-TB
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600 mg/day linezolid was taken for 238 days; subsequently
300 mg/day was used for 102 days and was then stopped due to
persistent neuropathy symptoms.
Of the 24 patients, 10 (42%) had a body mass index of
,18 kg/m2, indicating moderate undernutrition.14 The occurrence
of peripheral neuropathy was not different between patients with a
body mass index of ,18 kg/m2 (4/10, 40%, 95% CI 12%–74%)
and those with a body mass index of 18 kg/m2 (4/14, 29%, 95%
CI 8%–58%). Peripheral neuropathy occurred more frequently in
patients with diabetes mellitus (2/3, 67%, 95% CI 9%–99%) than
in those without diabetes mellitus (6/21, 29%, 95% CI 9%–48%).
Sputum culture conversion, which was defined as two or more
consecutive negative cultures taken at least 4 weeks apart, was
achieved in 22 (92%, 95% CI 81%–100%) patients after a
median of 89 days from the start of linezolid treatment (IQR
48–160 days). One patient had persistent positive sputum despite
linezolid therapy (220 days) and one patient died of respiratory
failure during linezolid therapy (194 days). Radiographic
improvement, including disappearance or shrinkage of cavitary
lesion(s) on chest X-ray, was seen in 22 patients with sputum
culture conversion after linezolid treatment.
A patient was classified as cured if they completed treatment
and were consistently culture negative (with at least five negative
results) during the final 12 months of treatment.15 Of the 22
patients with sputum conversion, two patients were cured after
anti-TB treatment including continued linezolid therapy (550 and
729 days) and two patients were cured despite discontinuing line-
zolid therapy due to peripheral neuropathy (340 days) or economic
reasons (179 days). Another 18 patients were still taking linezolid
for a median duration of 350 days (range 284–655 days) with
culture conversion. Six patients underwent surgical resection for
MDR/XDR-TB during linezolid treatment.
A pharmacokinetic study was performed in 10 patients at least
7 days after beginning a daily 300 mg dose of linezolid (Figure 1).
The mean serum Cmin of linezolid was 2.1+1.3 mg/L (range
0.4–4.5 mg/L) and the mean serum Cmax was 11.6+4.4 mg/L
(range 1.5–15.9 mg/L). In a patient in whom treatment failed,
the Cmax and Cmin were 13.4 and 1.0 mg/L, respectively. The
patient with the lowest linezolid concentration (Cmax¼1.5,
Cmin¼0.4 mg/L) was cured after 729 days of linezolid therapy.
The MIC99 of linezolid for M. tuberculosis was 0.25 mg/L for
isolates from three patients and 0.5 mg/L for isolates from seven
patients, including a patient in whom treatment failed. The MIC
of linezolid was 0.5 mg/L for the H37Rv laboratory control strain.
Discussion
This is the first report on the efficacy and tolerability of a daily
300 mg dose of linezolid for treating MDR/XDR-TB. In this
study, 22 of 24 patients with MDR-TB, including 11 out of 12
patients with XDR-TB, achieved sputum culture conversion after
daily treatment with 300 mg of linezolid. Our cases had truly
‘intractable’ MDR/XDR-TB in many respects, including previous
long-term treatment with second-line drugs, high rates of resist-
ance to anti-TB drugs, sputum smear status and radiographic find-
ings. These findings suggest that a daily 300 mg dose of linezolid
is clinically effective in the treatment of MDR/XDR-TB.
Adverse side effects such as myelosuppression and neurotoxi-
city are a major problem during the prolonged use of linezolid.
A daily half-dose of linezolid (600 mg/day) appears to protect
Table 3. Combination drugs
Drug No. of patients
Ethambutol 0 (0%)
Pyrazinamide 4 (17%)
Streptomycin 2 (8%)
Kanamycin 9 (38%)
Capreomycin 7 (29%)
Amikacin 1 (4%)
Moxifloxacin 17 (71%)
Levofloxacin 4 (17%)
Prothionamide 6 (25%)
Cycloserine 19 (79%)
p-Aminosalicylic acid 7 (29%)
Rifabutin 5 (21%)
Amoxicillin/clavulanate 19 (79%)
Clarithromycin 14 (58%)
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Figure 1. Mean steady-state serum Cmax and Cmin of linezolid after the oral
administration of 300 mg once daily. The serum linezolid levels were
measured before (Cmin) and 2 h after (Cmax) the oral administration of
linezolid using an HPLC assay at least 7 days after beginning a daily 300 mg
dose of linezolid. The broken horizontal line represents the expected MIC
(1 mg/L) of linezolid for M. tuberculosis.
Table 2. Drug resistance rates
Drug Resistance rate
Isoniazid 24 (100%)
Rifampicin 24 (100%)
Ethambutol 22 (92%)
Pyrazinamide 21 (88%)
Streptomycin 17 (71%)
Kanamycin 12 (50%)
Capreomycin 7 (29%)
Ofloxacin 24 (100%)
Moxifloxacin 20 (83%)
Prothionamide 17 (71%)
Cycloserine 9 (38%)
p-Aminosalicylic acid 15 (63%)
Rifabutin 18 (75%)
Koh et al.
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against myelosuppression, but not neurotoxicity,10,11 as neuro-
toxicity is more closely related to the duration of treatment.16
The linezolid levels in plasma and epithelial lining fluid are
expected to exceed the M. tuberculosis MIC (0.5–1 mg/L) during
most of the dosing interval following the administration of various
oral doses.17,18 The long-term use of linezolid, even with a daily
dose of 600 mg, induces adverse effects, principally neurotoxicity,
by inhibiting mitochondrial protein synthesis in a dose-dependent
fashion.19 McKee et al.20 reported that the linezolid concentration
inhibiting 50% of mitochondrial protein synthesis (i.e. IC50) in rat
and rabbit hearts and in liver mitochondria is 3.37–5.26 mg/L.
Therefore, we hypothesized that the serum linezolid concentration
after a 300 mg dose would remain above the MIC for M. tubercu-
losis, and yet below the IC50 level, permitting efficacy against
MDR/XDR-TB without producing serious side effects.
In our previous studies, a daily dose of 600 mg of linezolid
therapy was associated with peripheral neuropathy in 50%–70%
of MDR-TB patients, and we found that linezolid treatment
should be discontinued in all patients who developed peripheral
neuropathy.10,11 In this study, peripheral neuropathy developed
in 4 out of 17 (24%) patients who received 300 mg/day linezo-
lid, while neurotoxicity occurred in 4 out of 7 (57%) patients
who were initially given 600 mg/day linezolid. Linezolid had to
be discontinued in two patients only, including one patient who
was initially prescribed 600 mg/day and had the dose reduced to
300 mg/day. Bone marrow suppression developed in one patient
who was initially given 600 mg/day linezolid.
The absorption of linezolid after oral dosing is rapid and
Cmax is achieved 1–2 h after dosing.
17 The oral bioavailability
approaches 100%. In addition, linezolid can penetrate bronchial
mucosa, alveolar macrophages and epithelial lining fluid well.18
Our study revealed that both the serum Cmin and serum Cmax
after oral dosing of linezolid 300 mg/day were higher than the
MIC for the infecting M. tuberculosis strain.
The present study has several important limitations. This
retrospective study included a small group of patients, and this
was not a randomized clinical trial including a control group
who did not receive linezolid therapy. In addition, the majority
of patients were still on treatment at the time the analyses were
performed. Therefore, it is hard to conclude anything about cure
or the long-term efficacy of a daily dose of 300 mg of linezolid.
In conclusion, a daily dose of 300 mg of linezolid may be
enough to keep the serum concentrations of linezolid above the
MIC for M. tuberculosis, and may be useful for increasing the
chances of culture conversion in the treatment of patients with
intractable MDR/XDR-TB and possibly reducing or delaying the
development of side effects, especially neurotoxicity. The
present results encourage further research into the use of a
300 mg dose of linezolid for MDR/XDR-TB patients.
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